Quantum Biopharma Ltd.

Quantum Biopharma Ltd. is a biopharmaceutical company that operates through two segments: Biopharmaceutical Innovation and Strategic Investments. The company focuses on researching and developing a portfolio of assets and biotech solutions for neurodegenerative, inflammatory, metabolic, and alcohol misuse disorders, with drug candidates at various development stages. Its lead compound, Lucid-MS, is a patented new chemical entity currently in a Phase 2 clinical trial. Lucid-MS aims to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, as demonstrated in preclinical models. Quantum Biopharma Ltd. also develops FSD-PEA, which is preparing for a Phase 2 trial for inflammatory diseases like mast cell activation syndrome. Other developments include Lucid-PSYCH for major depressive disorder and unbuzzd, a dietary supplement for alcohol misuse. The Strategic Investments segment includes a portfolio of loans secured by residential property. The company, founded in 1998, changed its name from FSD Pharma Inc. to Quantum Biopharma Ltd. in August 2024 and is based in Toronto, Canada.